A5019984630- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- T-cell and B-cell Immunology
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Surgical Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- T-cell and Retrovirus Studies
- Immune cells in cancer
- Heat shock proteins research
- Colorectal and Anal Carcinomas
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Vector-Borne Animal Diseases
- Cancer, Stress, Anesthesia, and Immune Response
- Single-cell and spatial transcriptomics
- Lung Cancer Treatments and Mutations
- Hormonal Regulation and Hypertension
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Cancer Cells and Metastasis
National Cancer Centre Japan
2017-2025
Chiba Cancer Center
2016-2025
Nagoya University
2016-2025
Kyoto University
2010-2025
National Cancer Center Hospital East
2016-2025
Kindai University
2025
Institute of Cancer Research
2023
Nagoya University Hospital
2017-2022
National Cancer Center
2016-2021
St. Luke's International Hospital
2021
In a recent report, [Zhang et al. (2003) N. Engl. J. Med. 348, 203–213], the presence of CD3 + tumor-infiltrating lymphocytes (TILs) was found to correlate with improved survival in epithelial ovarian cancer. We performed immunohistochemical analysis for TILs and cancer testis antigens 117 cases The interrelationship between subpopulations expression investigated, as well overall survival. median follow-up patients 31 months. Patients higher frequencies intraepithelial CD8 T cells...
Significance PD-1 blockade is a cancer immunotherapy effective in various types of cancer. However, we observed rapid progression, called hyperprogressive disease (HPD), ∼10% advanced gastric patients treated with anti–PD-1 monoclonal antibody. Tumors HPD possessed highly proliferating FoxP3 + Treg cells after treatment, contrasting their reduction non-HPD tumors. In vitro augmented proliferation and suppressive activity human cells. Likewise, murine that were deficient signaling more...
This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer.Enrolled patients received in dose-finding part to estimate the maximum tolerated dose. Additional were enrolled dose-expansion part. Regorafenib 80-160 mg was administered once daily 21 days on/7 off with 3 mg/kg every 2 weeks. The primary end point dose-limiting toxicity (DLT) during first 4 weeks recommended dose.Fifty (25 each cancer) enrolled. All had ≥ previous lines chemotherapy, including...
Significance Regulatory T (Treg) cells expressing the transcription factor FOXP3 play a critical role in suppressing antitumor immune responses. Here we found that, compared with peripheral blood cells, tumor-infiltrating contained higher frequency of effector Tregs, which are defined as hi and CD45RA − , terminally differentiated, most suppressive. Effector Treg but not lo + naïve predominantly expressed C-C chemokine receptor 4 (CCR4) both cancer tissues blood. In vivo or vitro anti-CCR4...
CD4+Foxp3+ T regulatory (Treg) cells control many facets of immune responses ranging from autoimmune diseases, to inflammatory conditions, and cancer in an attempt maintain homeostasis. Natural Treg (nTreg) develop the thymus constitute a critical arm active mechanisms peripheral tolerance particularly self-antigens. A growing body knowledge now supports existence induced (iTreg) which may derive population conventional CD4+ cells. The fork-head transcription factor (Foxp3) typically is...
The clinical efficacy of anti-PD-1 (programmed cell death-1) monoclonal antibody (mAb) against cancers with oncogenic driver gene mutations, which often harbor a low tumor mutation burden, is variable, suggesting different contributions each to immune responses. Here, we investigated the immunological phenotypes in microenvironment (TME) epidermal growth factor receptor (EGFR)-mutated lung adenocarcinomas, for mAb largely ineffective. Whereas EGFR-mutated adenocarcinomas had noninflamed TME,...
Abstract Purpose: FoxP3+ Tregs inhibit immune responses against tumors. KW-0761 is a humanized anti-human CCR4 monoclonal antibody (mAb) that has antibody-dependent cellular cytotoxicity activity. Depletion of CCR4-expressing CD4 by infusion was investigated in solid cancer patients. Experimental Design: We conducted phase Ia clinical trial 7 lung and 3 esophageal Toxicity, efficacy, changes lymphocyte subpopulations, including Tregs, induction were analyzed. Results: The results showed dose...
Immunological tolerance to self requires naturally occurring regulatory T (T reg ) cells. Yet how they stably control autoimmune cells remains obscure. Here, we show that can render self-reactive human CD8 + anergic (i.e., hypoproliferative and cytokine hypoproducing upon antigen restimulation) in vitro, likely by controlling the costimulatory function of antigen-presenting Anergic were naïve phenotype, lower than activated cell receptor affinity for cognate antigen, expressed several...
Several studies have established a correlation between the VEGF-VEGFR2 axis and an immunosuppressive microenvironment; this immunosuppression can be overcome by anti-angiogenic reagents, such as ramucirumab (RAM). However, little is known about immunological impact of reagents within tumor microenvironment in human clinical samples. This study aimed at investigating effects RAM on microenvironmental immune status cancers.